Haohai Bio reports slight revenue increase for 2024

Shanghai Haohai Biological Technology (SSE:688366) announced preliminary 2024 financial results, reporting a 1.64% increase in total revenue to 269.77 million RMB. While operating profit decreased by 2.19% to 49.63 million RMB, net profit attributable to shareholders rose slightly by 0.97% to 42.02 million RMB. Basic earnings per share increased by 2.86% to 1.80 RMB. The company's total assets reached 712.47 million RMB, a slight increase of 0.27% from the beginning of the year. The increase in share capital is attributed to a capital reserve transfer of equity completed in June 2024. The final audited financial data will be disclosed in the company's 2024 annual report.